Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly
Summary
This study compares the effectiveness of the dietary supplement Gepaktiv with standard medications (UDCA and Ademetionine) in patients with fatty liver disease (MAFLD) and liver enlargement (hepatomegaly). Key points: * Participants will receive either Gepaktiv, UDCA, or Ademetionine for 15 days * Doctors will monitor liver health through blood tests and ultrasound scans * The study will check if Gepaktiv helps improve liver function as effectively as standard treatments. Main measurements: * Changes in liver enzyme levels (ALT, AST) * Reduction in liver size * Improvement in fat accumulation (steatosis) measured by FibroScan This research may provide evidence for a new natural option to support liver health.Data analysis will be done by an independent biostatistics
Timeline
- Start
- 2025-06-19
- Primary completion
- 2025-07
- Completion
- 2025-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ademetionine | Unknown | 800 mg | — |
| Comparator | Ademetionine | Unknown | 1600 mg | — |
| Subject | Gepaktiv | Unknown | 250 mg | — |
| Comparator | Ursodeoxycholic Acid | Small molecule | 10 mg/kg | — |
| Comparator | Ursodeoxycholic Acid | Small molecule | 15 mg/kg | — |